Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
Details : PHVS416 (deucrictibant) is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist currently in development to prevent the occurrence of bradykinin-mediated angioedema attacks.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2025
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onasemnogene Abeparvovec
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis Phase III Data Shows Efficacy of Onasemnogene Abeparvovec in SMA
Details : Zolgensma (onasemnogene abeparvovec) is USFDA approved, one time gne therapy that acts as SMN1 gene stimulant. It is indicated for the treatment of spinal muscular atrophy.
Product Name : Zolgensma
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 19, 2025
Lead Product(s) : Onasemnogene Abeparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onasemnogene Abeparvovec
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis Phase III Study of Onasemnogene Abeparvovec Meets Primary Endpoint in SMA
Details : Zolgensma (onasemnogene abeparvovec) is USFDA approved, one time gne therapy that acts as SMN1 gene stimulant. It is indicated for the treatment of spinal muscular atrophy.
Product Name : Zolgensma
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 30, 2024
Lead Product(s) : Onasemnogene Abeparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : SPRIM Global Investments
Deal Size : $2.5 million
Deal Type : Financing
Details : The financing will be used to fund the upcoming Phase 3 studies of ColiFin (colistimethate sodium), an inhaled antibiotic therapeutic for the management of chronic infections in cystic fibrosis patients.
Product Name : ColiFin
Product Type : Antibiotic
Upfront Cash : Undisclosed
August 15, 2023
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : SPRIM Global Investments
Deal Size : $2.5 million
Deal Type : Financing
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : SPRIM Global Investments
Deal Size : Undisclosed
Deal Type : Partnership
Details : This collaboration is expected to provide capitalization through significant clinical milestones in ColiFin®’s Phase 3 development. ColiFin® (colistimethate sodium) is being developed for the treatment of chronic lung infections in cystic fibrosis (C...
Product Name : ColiFin
Product Type : Antibiotic
Upfront Cash : Undisclosed
August 02, 2023
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : SPRIM Global Investments
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Tadekinig Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : r-hIL-18BP (tadekinig alfa) is a recombinant human interleukin-18 binding protein inhibiting IL18. It captures excess free IL-18 mimicking the normal physiological situation, and therefore represents a well differentiated approach for the treatment of IL...
Product Name : r-hIL-18BP
Product Type : Protein
Upfront Cash : Inapplicable
July 03, 2023
Lead Product(s) : Tadekinig Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Acer Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACER-001 (sodium phenylbutyrate) is an immediate-release, polymer coated, multi-particulate formulation of sodium phenylbutyrate for oral administration via suspension, that is designed to improve palatability.
Product Name : Olpruva
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 08, 2022
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Acer Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delandistrogene Moxeparvovec
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Chugai Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the license agreement between Roche and Chugai, Chugai obtained exclusive marketing right in Japan for delandistrogene moxeparvovec (SRP-9001), an investigational gene therapy for Duchenne muscular dystrophy.
Product Name : SRP-9001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 16, 2021
Lead Product(s) : Delandistrogene Moxeparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Chugai Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Lucerastat
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lucerastat demonstrated a substantial reduction in levels of the Fabry-disease biomarker plasma Gb3 after 6 months of treatment. The potential effect of lucerastat on kidney function over 6 months of treatment was evaluated at the interim analysis of the...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2021
Lead Product(s) : Lucerastat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lucerastat
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Idorsia Announces the Results of MODIFY, a Phase 3 Study of Lucerastat in Fabry disease
Details : The safety, tolerability, pharmacodynamics, and pharmacokinetics of oral lucerastat were evaluated in study in adult patients with Fabry disease. In this single-center, open-label, randomized study, 10 patients with Fabry disease were randomized to lucer...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 10, 2021
Lead Product(s) : Lucerastat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable